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Angelman Syndrome is a debilitating neurological
disorder caused by mutation of the E3 ubiquitin
ligase Ube3A, a gene whose mutation has also
recently been associated with autism spectrum
disorders (ASDs). The function of Ube3A during
nervous system development and how Ube3A muta-
tions give rise to cognitive impairment in individuals
with Angleman Syndrome and ASDs are not clear.
We report here that experience-driven neuronal
activity induces Ube3A transcription and that
Ube3A then regulates excitatory synapse develop-
ment by controlling the degradation of Arc, a synaptic
protein that promotes the internalization of the
AMPA subtype of glutamate receptors. We find that
disruption of Ube3A function in neurons leads to
an increase in Arc expression and a concomitant
decrease in the number of AMPA receptors at
excitatory synapses. We propose that this deregula-
tion of AMPA receptor expression at synapses may
contribute to the cognitive dysfunction that occurs
in Angelman Syndrome and possibly other ASDs.
INTRODUCTION
Angelman Syndrome (AS) is a neurodevelopmental disorder
characterized by motor dysfunction, severe mental retardation,
speech impairment, seizures, and a high prevalence of autism
(Williams et al., 2006). Genetic studies revealed that AS is asso-
ciated with maternal deletions of chromosome 15q11-q13,
paternal chromosome 15 uniparental disomy, or rare imprinting
defects that affect the transcription of genes within 15q11-q13
(Clayton-Smith and Laan, 2003). Recent studies indicate that
failure to inherit a normal maternal copy of the UBE3A gene704 Cell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc.(which resides within 15q11-q13) accounts for 85%–90% of
AS cases, and specific loss-of-function mutations in human
UBE3A have been identified in a subset of affected individuals
(Kishino et al., 1997; Matsuura et al., 1997).
The role of Ube3A mutations in AS is supported by targeted
inactivation of Ube3a in mice (Jiang et al., 1998; Miura et al.,
2002). Upon inheritance of the mutation through the maternal
germline, the mutant mice display features of AS. The finding
that imprinting of Ube3A occurs in specific brain regions rein-
forces the idea that loss of Ube3A function in the nervous system
underlies AS (Jiang et al., 1998; Albrecht et al., 1997).
The study of Ube3A mutations also provides insight into the
causes of autism. Autism spectrum disorders (ASDs) are
complex disorders characterized by impairment in social inter-
actions and the occurrence of repetitive behaviors. Despite the
high prevalence of ASDs, little is known about the etiology of
these disorders. Nonetheless, there is a significant genetic
component to ASDs, and thus considerable effort has gone
into identifying genetic mutations that cause ASDs. These
studies suggest thatUbe3A is a candidate ASD gene. Abnormal-
ities within chromosomal region 15q11-q13 are among the most
prevalent mutations identified in ASDs, accounting for 1%–2%
of all ASD cases (Sutcliffe et al., 2003; Cook et al., 1997). Recent
reports indicate that copy number variance within the Ube3A
locus is associated with autism (Glessner et al., 2009).
Despite the critical role that Ube3A plays in human cognitive
function, little is known about Ube3A’s contribution to nervous
system development or how the mutation of Ube3A leads to
cognitive impairment. Electrophysiological experiments have
demonstrated impaired long-term potentiation (LTP) in Ube3A
knockout mice (Jiang et al., 1998). Additionally, a recent study
implicates Ube3A in experience-dependent plasticity (Yashiro
et al., 2009). While these experiments demonstrate a crucial
role for Ube3A in synaptic transmission, the mechanisms by
which Ube3A regulates synaptic function are poorly understood.
Possible insight into how Ube3A functions may come from the
finding that Ube3A is a member of the E3 ubiquitin ligase family
of enzymes, a class of proteins that catalyzes the addition of
ubiquitin moieties to target substrates, often leading to the
degradation of the ubiquitinated protein. Genetic studies indi-
cate that the ubiquitin ligase activity of Ube3A is necessary for
normal human cognitive function inasmuch as disruption of
this activity leads to AS (Cooper et al., 2004). Nevertheless, the
neuronal substrates of Ube3A that mediate its effects on
synaptic function remain unknown.
In this study, we sought to understand how disruption of
Ube3A results in synaptic dysfunction. We find that Ube3A is
a neuronal activity-regulated protein that controls synaptic
function by ubiquitinating and degrading the synaptic protein
Arc. In the absence of Ube3A, elevated levels of Arc accumulate
in neurons, resulting in the excessive internalization of AMPA
receptors (AMPARs) at synapses and impaired synaptic func-
tion. This impaired AMPAR trafficking may be a cause of the
cognitive dysfunction that occurs in AS. These findings suggest
potential therapeutic targets for treating AS, a disorder for which
there is currently no effective therapy.
RESULTS
Activity-Dependent Regulation of Ube3A
One clue as to how Ube3A might function in nervous system
development comes from the observation that the symptoms
of AS and ASDs first become apparent within the first years of
a child’s life (Williams et al., 2006), during which sensory
experiences play a key role in shaping neuronal connectivity.
The effect of environmental cues on cognitive development is
mediated in part by the release of glutamate at excitatory
synapses. This triggers a program of gene expression that plays
a critical role in synapse development (Greer and Greenberg,
2008). We considered the possibility that AS may arise from
a deficit in activity-dependent regulation of Ube3A.
We find that the expression ofUbe3Amessenger RNA (mRNA)
in cultured neurons is significantly increased by either membrane
depolarization or glutamate receptor activation (Figure 1A). Con-
versely, blocking neuronal activity with inhibitors of NMDARs,
AMPARs and sodium channels results in a decrease in Ube3A
mRNA expression (Figure S1A available online). Ube3A protein
levels mirror the change in mRNA level under these conditions
(Figure 1B and Figures S1B and S1C).
We next asked whether Ube3A expression is induced by
neuronal activity in the intact mouse brain. During kainate-
induced seizures,Ube3AmRNA and protein levels are increased
compared to control (Figures S1D and S1E). Ube3A is also
induced in response to environmental stimuli that trigger experi-
ence-dependent synaptic development (Figure 1C and Fig-
ure S1F). Mice in a cage containing novel objects to induce
exploratory behavior exhibited increased Ube3A mRNA and
protein expression compared to mice in a standard laboratory
cage (Figure 1C and Figure S1F). These results demonstrate
that Ube3A mRNA and protein levels are regulated by synaptic
activity both in culture and in the intact brain. These findings raise
the possibility that synaptic glutamate release during early life
experiences activates Ube3A expression and that the absence
of experience-dependent Ube3A induction may contribute to
the neurological impairment in AS.We investigated the mechanism by which neuronal activity
triggers Ube3A induction. Analysis of Ube3A transcripts
present in expressed sequence tag databases revealed three
distinct mRNA transcripts that are likely transcribed from
unique promoters. Of the Ube3A transcripts, those initiating
from promoters 1 and 3 are induced by neuronal activity
(Figure S1G), and their promoters contain binding sites for the
activity-regulated transcription factor MEF2. These sites are
conserved across phylogeny and lie within 2 kB of the putative
transcriptional start sites of the two activity-regulated Ube3A
transcripts (see below). The presence of potential MEF2-
binding sites within Ube3A promoters was of interest because
MEF2 is an activity-regulated transcription factor that controls
synapse development and regulates genes implicated in
ASDs (Flavell et al., 2006; Flavell et al., 2008; Morrow et al.,
2008).
Chromatin immunoprecipitation experiments revealed that
DNA fragments corresponding to Ube3A promoters 1 and 3 are
enriched in anti-MEF2 immunoprecipitates (Figure 1D and data
not shown). By contrast, there was no enrichment for DNA
sequences surrounding Ube3A promoter 2 (Figure 1D). These
data suggest that MEF2 may directly control the activity-depen-
dent transcription of Ube3A from promoters 1 and 3.
The neuronal activity-dependent induction of Ube3A pro-
moter 1- and 3-driven mRNA transcripts and Ube3A protein
are significantly reduced in neurons infected with lentiviruses
encoding short hairpin RNAs (shRNAs) targeting the MEF2
family members MEF2A and MEF2D (Figures 1E and 1F). By
contrast, the expression of Ube3A promoter 2-dependent
mRNA transcripts, as well as GAPDH and beta3-tubulin, is
unaffected by the presence of MEF2 shRNA (Figure 1E). These
experiments indicate that in response to neuronal activity,
Ube3A promoter 1- and 3-driven mRNA transcripts and
Ube3A protein expression are induced by a MEF2-dependent
mechanism.
Identification of Ube3A Substrates
Regulation of Ube3A mRNA expression by neuronal activity
along with the association ofUbe3Awith AS led us to investigate
the role of Ube3A in nervous system development. Point muta-
tions within the Ube3A coding region have been associated
with AS, nearly all of which abrogate its E3 ubiquitin ligase
activity (Cooper et al., 2004), suggesting that the catalytic activity
of Ube3A is important for nervous system development.
Although several Ube3A substrates have been identified in
nonneuronal cells, the identification of substrates of E3 ubiquitin
ligases has been challenging. To identify Ube3A substrates, we
employed a transgenic mouse in which a hemagglutinin epitope
tagged-version of ubiquitin (HA-ubiquitin) is knocked into the
HPRT locus (Ryu et al., 2007). These mice express similar levels
of free ubiquitin in their brains to those detected in the brains of
wild-type mice (Figure 2A). In addition, in the HA-ubiquitin
mice HA-ubiquitin appears to be efficiently incorporated into
substrates (Figures 2A and 2B). We crossed HA-ubiquitin
transgenic mice with wild-type or Ube3A knockout mice and
immunoprecipitated HA-ubiquitinated proteins from brain
lysates of these mice. We then compared ubiquitinated proteins
in wild-type and Ube3A knockout mice using quantitative massCell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc. 705
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Figure 1. Regulation of Ube3A by Neuronal
Activity
(A) qRT-PCR analysis of Ube3A mRNA extracted
from hippocampal neurons at E18 + 10 days
in vitro (DIV) stimulated for 5 hr with the indicated
agent (Glut., glutamate; Bic., bicuculline). Data
are presented as mean ± SEM from three indepen-
dent experiments. * indicates statistical signifi-
cance in pairwise comparison to control: p < 0.01
t test.
(B) Western blot analyses of Ube3A and beta-
tubulin. Protein lysates were collected from
E18 + 10 DIV hippocampal neurons after stimula-
tion with 55 mM KCl for 7 hr. Three independent
experiments were performed, and a representative
western blot is shown.
(C) qRT-PCR examining Ube3A and GAPDH
mRNA levels in hippocampi of mice placed in stan-
dard laboratory cages (control) or in cages with
novel objects (novel environment). The expression
ofUbe3A andGAPDH is normalized to the expres-
sion of beta-tubulin, which serves as an internal
standard. Data are presented as mean ± SEM
from three independent experiments. * indicates
statistical significance in pairwise comparison:
p < 0.05 t test.
(D) Chromatin immunoprecipitation with control or
anti-MEF2 antibodies. PCR amplification is per-
formed on genomic regions corresponding to the
promoter regions of the three Ube3A transcripts.
(E) qRT-PCR analysis of the three Ube3A tran-
scripts in hippocampal neurons transduced with
lentivirus expressing either control shRNA or
shRNAs targeting MEF2A and MEF2D. Neurons
were stimulated with 55 mM KCl for 6 hr before
mRNA was harvested. Data are plotted as fold
induction of stimulated cells over unstimulated
cells. Data are presented as mean ± SEM from
three independent experiments. * indicates statis-
tical significance in pairwise comparison: p < 0.01
t test.
(F) Western blot analyses of MEF2D, MEF2A,
Ube3A, and the loading control Vav2. Protein
lysates were collected from hippocampal neurons
at E18 + 10 DIV. Neurons were uninfected or trans-
duced with lentivirus encoding a control shRNA
or shRNA targeting MEF2A and MEF2D at E18 +
3 DIV. This experiment was performed three times
independently, and a representative western blot
is shown here.
See also Figure S1.spectrometry. We reasoned that if a given protein were a
substrate of Ube3A, then in the absence of Ube3A it would be
less ubiquitinated and thus less efficiently precipitated with
anti-HA antibodies. We therefore sought to identify HA-ubiquiti-
nated proteins whose abundance was decreased in Ube3A
knockout mice.
We identified the protein Sacsin as a candidate Ube3A
substrate. We found peptides corresponding to ubiquitinated
Sacsin in brain lysates of wild-type but not Ube3A knockout
mice, suggesting that Sacsin might not be efficiently ubiquiti-
nated in the absence of Ube3A (Figure 2C). Sacsin is of interest
as it is mutated in Charelvoix-Saguenay spastic ataxia, a neuro-706 Cell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc.logical disorder with similarities to AS (Engert et al., 2000).
However, little is known about Sacsin’s role in nervous system
development and the large size of the Sacsin protein suggested
it would be difficult to study. Nevertheless, we found that
Sacsin has a 75 amino acid stretch that has similarity to a previ-
ously identified Ube3A substrate HHR23A (Figure 2D). This
region of homology corresponds to a well-characterized region
of HHR23A consisting of five amphipathic helices, suggesting
that the corresponding region in Sacsin may have a similar struc-
ture (Kamionka and Feigon, 2004). As the specificity of ubiquitin
ligases is most strongly determined by substrate binding, we
hypothesized that this region of similarity between Sacsin and
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Figure 2. Identification of a Ube3A Binding
Domain
(A) Analysis of ubiquitinated proteins in wild-type
and HA-ubiquitin mice. Western blots using an
anti-ubiquitin antibody were performed on cell
lysates (WCE) or anti-HA immunoprecipitates from
hippocampal mouse brain lysates prepared from
wild-type (WT) or HA-ubiquitin transgenic (HA)
mice. * indicates the presence of free ubiquitin.
(B) Analysis of ubiquitinated proteins in wild-type
and HA-ubiquitin mice. Western blots using an
anti-HA antibody were performed on cell lysates
(WCE) or anti-HA immunoprecipitations from
hippocampal mouse brain lysates from wild-type
(WT) or HA-ubiquitin transgenic (HA) mice. * indi-
cates the presence of free ubiquitin.
(C) Quantification of the relative abundance of
ubiquitinated Sacsin in the brain of wild-type and
Ube3A knockout mice. No peptides were detected
corresponding to ubiquitinated Sacsin in Ube3A
knockout mice.
(D) Sequence alignment of human Sacsin (amino
acids 3660–3735) and human HHR23A (amino
acids 231–285). Identical residues are in red and
similar residues are in blue.
(E) Quantitative analysis of in vitro binding experi-
ments using recombinant HHR23A, a version of
HHR23A lacking the Ube3A binding domain
(DHHR23A), and GST-Ub3A after precipitation
with glutathione-Sepharose beads. Western blot-
ting was performed using an anti-HHR23A anti-
body. Data are presented as mean ± SEM from
three independent experiments.HHR23A might serve as a Ube3A binding domain (UBD) that
might be present in other Ube3A targets.
To test this hypothesis, we generated a mutant form of
HHR23A (DHHR23A) that lacks the UBD and assessed its ability
to interact with, and be ubiquitinated by Ube3A. While wild-type
HHR23A efficiently interacts with Ube3A, mutation of the UBD in
HHR23A blocks this interaction (Figure 2E). Likewise, this
domain is required for Ube3A to ubiquitinate HHR23A (data not
shown). These results suggest the existence of a motif on
Ube3A substrates that mediates binding to Ube3A.
A search of mammalian genomes for proteins that contain
the UBD identified proteins including the synaptic protein Arc
and the RhoGEF ephexin 5 as potential Ube3A substrates
(Figure 3A) (S.S. Margolis and M.E.G., unpublished data).
We focused our attention on Arc as Arc regulates the traffick-
ing of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate
(AMPA) type of glutamate receptors at synapses (Chowdhury et
al., 2006; Rial Verde et al., 2006; Shepherd et al., 2006). If Arc is
a substrate of Ube3A, such a finding could potentially begin to
explain Ube3A’s role in synaptic function. Furthermore, like
Ube3A, Arc transcription is regulated by neuronal activity
through the action of MEF2 family transcription factors (Flavell
et al., 2006), suggesting that these two proteins might function
together in response to synaptic activation.
To assess whether Arc is a Ube3A substrate, we asked
whether Arc and Ube3A interact. Purified Arc binds Ube3A in
a manner that is dependent upon the UBD within Arc (Figures
3B and 3C). Coimmunoprecipitation experiments using mousebrain extracts confirmed that Arc and Ube3A also interact in
the intact brain (Figure S2A). We then performed in vitro ubiquiti-
nation assays using purified recombinant proteins. Ube3A
ubiquitinated Arc in vitro but did not ubiquitinate the control
proteins p53 or MeCP2 (Scheffner et al., 1993) (Figure 3D and
data not shown). A catalytically inactive form of Ube3A (Ube3A
C833A) was incapable of catalyzing the ubiquitination of Arc
(Kumar et al., 1999) (data not shown and see below).
To test whether Ube3A promotes the ubiquitination of Arc
within cells, we transfected HEK293T cells with Arc and either
Ube3A C833A or wild-type Ube3A. Coexpression of wild-type
Ube3A, but not Ube3A C833A, led to a decrease in the level of
Arc (Figure 3E). Incubation of transfected HEK293T cells with
the proteasome inhibitor MG132 blocked Ube3A-mediated
degradation of Arc, suggesting that Ube3A degrades Arc via
the ubiquitin proteasome (Figure S2B). The ubiquitination of
Arc by Ube3A was confirmed by mass spectrometry (Figures
S2C and S2D).
We next compared Arc expression in the brains of wild-type
and Ube3A knockout mice. As the expression of both Ube3A
and Arc is enhanced by neuronal activity, we exposed the mice
to kainic acid or an enriched environment to boost the levels of
Ube3A and Arc protein. Under these conditions, we detect higher
levels of Arc protein in Ube3A knockout mice than in wild-type
controls (Figures 3F–3H). These findings suggest that Ube3A
ubiquitination of Arc in the wild-type brain contributes to Arc
degradation. In contrast to Arc, the activity-dependent phos-
phorylation of the transcriptional regulator MeCP2 and theCell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc. 707
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Figure 3. Arc Is a Ube3A Substrate
(A) Sequence alignment of Arc (amino acids 255–318) and HHR23A (amino acids 233–290). Identical residues are in red and similar residues are in blue. We would
like to note that as the UBD may represent a sequence that encodes a particular protein folding structure, a strict one-to-one map of specific residues is not
observed. Dashed lines indicate a gap in sequence.
(B) In vitro binding experiments using recombinant Arc, ArcDUBD, and GST-tagged Ube3A, precipitated with glutathione Sepharose beads and western blotted
with an anti-Arc antibody.
(C) Quantitative analysis of in vitro binding experiments using recombinant Arc, or ArcDUBD, and Ube3A. Western blotting was performed with an anti-Arc anti-
body. Percentage binding refers to the percent of Arc bound to Ube3A relative to the input. Data are presented as mean ± SEM from three independent exper-
iments. * indicates statistical significance p < 0.01, t test.
(D) In vitro ubiquitination assay of Arc in the presence of Ubiquitin (Ub) and/or Ube3A.
(E) Western blot analysis using anti-Arc, anti-Ube3A, or anti-actin antibodies on lysates from HEK293T cells transfected with the indicated constructs.
(F) Western blot analysis of protein lysates prepared from the hippocampi of wild-type and Ube3A knockout mice which had been injected with kainic acid.
Western blots performed with anti-MeCP2, anti-phospho-MeCP2, and anti-Arc antibodies as indicated. Three individual experiments representing at least
five animals per genotype were performed, and a representative example is shown.
(G) Quantification of Arc protein by western blot analysis of protein lysates prepared from hippocampi of wild-type and Ube3A knockout mice which had been
exposed to an enriched environment. Data represent mean ± SEM from four animals of each genotype. * denotes significance in pairwise comparison to control:
p < 0.01 t test.
(H) Quantification of Arc protein by western blot analysis of protein lysates prepared from synaptosomes isolated from hippocampi of wild-type and Ube3A
knockout mice that had been injected with kainic acid. Data represent mean ± SEM from three animals of each genotype. * denotes significance in pairwise
comparison to control: p < 0.05 t test.
(I) Real-time quantitative PCR analysis ofArcmRNA extracted from wild-type andUbe3A knockout mice seized with kainic acid used in (F). Data are presented as
mean ± SEM from three independent experiments.
See also Figure S2.induction of the activity-regulated transcription factor NPAS4 are
similar in wild-type and Ube3A knockout brains, suggesting that
the increase in Arc in Ube3A knockout mouse brain is not the708 Cell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc.result of an overall increase in the activity-dependent gene
response (Figure 3F and data not shown) (Zhou et al., 2006; Lin
et al., 2008). Furthermore, Arc mRNA levels are similar in the
brains of wild-type and Ube3A knockout mice, indicating that
the increase in the level of Arc protein detected in Ube3A
knockout neurons is likely due to a defect in Ube3A-mediated
degradation of Arc (Figure 3I). Given that Arc is ubiquitinated by
Ube3A in vitro and in intact cells and that the level of Arc protein
is significantly higher in Ube3A knockout mice, we conclude
that Arc is a Ube3A substrate and that the decreased ubiquitina-
tion of Arc in Ube3A knockout mice results in increased levels
of Arc in the brains of these animals.
Regulation of AMPA Receptor Expression and Function
by Ube3A
Arc regulates the surface expression of AMPA receptors
(AMPARs), mediators of fast excitatory neurotransmission in
the CNS. Reduction of Arc expression leads to an increase in
the surface expression of AMPARs, whereas increasing Arc
levels decreases the plasma membrane expression of AMPARs
(Chowdhury et al., 2006; Rial Verde et al., 2006; Shepherd et al.,
2006). As Arc levels are elevated in the absence of Ube3A, it is
possible that there is a concomitant decrease in the expression
of AMPARs on the plasma membrane. Such a finding would
suggest a mechanism for the cognitive dysfunction observed
in individuals with AS.
We asked whether reduction of Ube3A expression decreases
the plasma membrane expression of AMPARs. We decreased
Ube3A expression by transfecting neurons with shRNAs that
target Ube3A expression and then assessed the surface expres-
sion of AMPARs (Figures S3A and S3B). We focused on the
GluR1 subunit of the AMPA receptor, as GluR1 insertion into
the plasma membrane is regulated by neuronal activity and by
Arc (Newpher and Ehlers, 2008; Kessels and Malinow, 2009;
Rial Verde et al., 2006; Shepherd et al., 2006). To examine
GluR1 expression at the plasma membrane of neurons, we
stained hippocampal neurons with anti-GluR1 antibodies under
nonpermeabilizing conditions and quantified the number of
GluR1 puncta expressed on the cell surface. Expression of either
of two shRNAs targeting Ube3A results in a reduction in the
levels of GluR1 expressed at the plasma membrane that is
rescued by coexpression of an RNA interference (RNAi)-resis-
tant form of Ube3A (Figure 4A and Figure S3C). This decrease
in surface GluR1 was not due to a change in the expression of
AMPARs, as wild-type and Ube3A-deficient cells expressed
similar levels of GluR1 and GluR2 subunits (data not shown).
Furthermore, the plasma membrane expression of NR1 subunits
of the NMDA receptor was unaltered in Ube3A-deficient cells
(Figure 4B).
As AMPA receptors are trafficked in and out of synapses, we
examined the effect of Ube3A knockdown on surface postsyn-
aptic AMPA levels, quantifying the number of GluR1 cell surface
puncta that colocalize with the postsynaptic scaffolding protein
PSD95. We find that shRNAs targeting Ube3A cause a reduction
in the number of GluR1 puncta colocalizing with PSD95, indi-
cating that Ube3A regulates recruitment of AMPA receptors to
the postsynaptic region (Figure 4C).
We asked whether AMPAR endocytosis is enhanced in the
absence of Ube3A. We used GluR1-specific antibodies to label
surface AMPARs on neurons transfected with shRNAs targeted
to Ube3A. After membrane depolarization to induce the endocy-tosis of synaptic AMPARs, anti-GluR1 antibodies bound to the
remaining surface GluR1 subunits were removed by acid strip-
ping (Man et al., 2007). Subsequent permeabilization of the
cells and staining with fluorescent secondary antibodies to
detect the internalized component of GluR1 revealed increased
levels of endocytosed GluR1 in Ube3A shRNA-expressing cells
compared to control shRNA-transfected neurons (Figure 4D).
Thus, the decreased expression of AMPARs in the plasma
membrane of synapses of Ube3A-deficient cells is due, at least
in part, to an increase in AMPAR endocytosis.
To investigate whether increased AMPAR endocytosis affects
AMPAR function at synapses, we recorded miniature excitatory
postsynaptic currents (mEPSCs) in neurons expressing Ube3A-
directed shRNAs. Compared to control shRNAs, the transfection
of Ube3A shRNAs results in a significant decrease in mEPSC
frequency with no change in mEPSC amplitude (Figures 4E–
4G). This decrease in mEPSC frequency could be rescued by
coexpression of an RNAi-resistant form of Ube3A. As mEPSC
frequency is a measure of AMPAR-mediated synaptic transmis-
sion, this observation suggests that AMPAR function is altered at
synapses of Ube3A deficient neurons.
The observation that when Ube3A expression is knocked
down there is a reduction in mEPSC frequency with no change
in mEPSC amplitude could be explained by any of three possi-
bilities: (1) a reduction in the number of synapses formed on
the Ube3A deficient neuron, (2) reduced presynaptic proba-
bility of neurotransmitter release from neurons that synapse
onto Ube3A deficient neurons, or (3) a subset of synapses
that form on Ube3A-deficient neurons could lack AMPA recep-
tors and thus would be ‘‘silent synapses,’’ not readily detected
by mEPSC recordings. To distinguish between these possibil-
ities, we determined whether there are fewer synapses formed
when Ube3A is knocked down. At the time point of analysis
where we detect reduced mEPSC frequency, we observe no
significant change in dendritic spine density or the number
of synapses that form on Ube3A shRNA-expressing neurons
(Figures S3D and S3E). These findings, and the absence of
any detectable change in the formation of inhibitory synapses,
neuronal morphology, or cell survival when Ube3A expression
is knocked down (data not shown), suggest that the decrease
in mEPSC frequency does not reflect a decrease in the
number of synaptic connections formed on Ube3A-deficient
neurons.
Although we cannot rule out the possibility that a decrease in
Ube3A expression in the postsynaptic neuron reduces the
presynaptic probability of release, we favor the hypothesis that
the loss of Ube3A leads to the elimination of AMPAR expression
from a subset of synapses for a number of reasons, including
the following: (1) loss of Ube3A function results in an increase
in the levels of Arc, a protein whose expression has been shown
to promote the endocytosis of AMPAR, (2) in the absence of
Ube3A, we observe fewer GluR1 puncta that colocalize with
PSD95, suggesting that when the level of Ube3A protein is
reduced there are synapses that may not express AMPARs,
and (3) there is a reduction in the ratio of AMPA/NMDA
receptor-mediated transmission in Ube3A knockout neurons
(see below), consistent with the idea that some synapses that
form on Ube3A-deficient neurons lack AMPARs.Cell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc. 709
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Figure 4. Ube3A Regulates AMPAR Func-
tion
(A) Quantification of plasma membrane expression
of AMPARs on E18 + 14 DIV hippocampal neurons
transfected at 10 DIV with GFP and vector control,
either of two shRNAs targeting Ube3A (RNAi 1
or 2), scrambled control shRNA (scRNAi 1 or 2),
a form of Ube3A that is resistant to Ube3A shRNA
(Ube3Ares), or Ube3A shRNA and Ube3A that is
RNAi resistant (Ube3Ares + RNAi 2). At least 35
neurons were imaged for each condition. Data
are presented as mean ± SEM from three indepen-
dent experiments. * indicates statistical signifi-
cance p < 0.05, ANOVA with a Bonferroni correc-
tion for multiple comparisons.
(B) Quantification of plasma membrane expression
of NMDA receptors on E18 + 14 DIV hippocampal
neurons transfected at 10 DIV with GFP and vector
control, either of two shRNAs targeting Ube3A
(RNAi 1 or 2), or a scrambled control shRNA
(scRNAi 1). At least 20 neurons were imaged
for each condition, and data are presented as
mean ±SEM from three independent experiments.
(C) Same as in (A) except only GluR1 puncta that
colocalize with PSD95 are counted. At least 29
neurons were imaged for each condition, and
data are presented as mean ± SEM from three
independent experiments. * indicates statistical
significance p < 0.05, ANOVA with a Bonferroni
correction for multiple comparisons.
(D) Quantification of internalized GluR1 receptors
from E18 + 14 DIV hippocampal neurons trans-
fected at 10 DIV with GFP plus vector, Ube3a
shRNA, or control scrambled shRNA. Data are
presented as mean ± SEM from three indepen-
dent experiments. * indicates statistical signifi-
cance p < 0.05, ANOVA with a Bonferroni correc-
tion for multiple comparisons.
(E) Representative mEPSC traces of control trans-
fected (top) or Ube3A RNAi transfected neurons
(bottom) used for analysis in (F) and (G).
(F) Quantification of mEPSC interevent interval
(the time between mEPSC events and thus
inversely proportional to mEPSC frequency) from
E18 + 14 DIV hippocampal neurons transfected
as in (A). Data are presented as mean ± SEM
from three independent experiments. * indicates
statistical significance p < 0.01, t test.
(G) Quantification of mEPSC amplitude from E18 + 14 DIV hippocampal neurons transfected as in (A). Data are presented as mean ± SEM from three indepen-
dent experiments.
See also Figure S3.Arc Mediates the Effect of Ube3A on AMPAR Trafficking
We asked whether Ube3A enhances AMPAR endocytosis by
ubiquitinating and degrading Arc. If the enhanced AMPAR
endocytosis observed after Ube3A knockdown is mediated by
the dysregulation of the ubiquitination of Arc, we would make
the following predictions: (1) Ube3A’s ubiquitin ligase activity
would be required for its effect on AMPAR endocytosis, (2) over-
expression of Arc would phenocopy the loss of Ube3A and
reduce AMPAR plasma membrane expression, and (3) in Ube3A-
deficient cells, restoring Arc expression to the level seen in wild-
type neurons should rescue the decrease in GluR1 surface
expression observed in the absence of Ube3A.710 Cell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc.To test these predictions, we examined whether the ubiquitin
ligase activity of Ube3A is required for Ube3A to promote
AMPAR expression at synapses. We generated a Ube3A mutant
in which the cysteine residue within the active site of the Ube3A
ligase is mutated to alanine (Ube3A C833A), reasoning that
when overexpressed this mutant should act in a dominant
interfering manner to block the ability of endogenous Ube3A to
ubiquitinate its substrates. We found this to be true as overex-
pression of Ube3A C833A blocks the ability of wild-type Ube3A
to ubiquitinate and degrade its substrates (Figures 5A–5C). To
determine whether Ube3A’s ubiquitin ligase activity is required
for Ube3A to enhance AMPAR expression at synapses, we
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Figure 5. Ube3A-Mediated Degradation of
Arc Affects AMPAR Cell Surface Expression
(A) In vitro ubiquitination assay of Arc or a version of
Arc in which all lysine residues are mutated to argi-
nine (ArcDK) in the presence of Ubiquitin (Ub),
Ube3A, or Ube3A C833A (C833A). Western blotting
analysis was performed with an anti-Arc antibody.
(B) Quantitative western blot analysis of protein
lysates from HEK293T cells transfected with the
indicated constructs. Western blots were per-
formed with an anti-Arc antibody, and the signals
were normalized to an actin loading control.
(C) Quantitative western blot analysis of protein
lysates from HEK293T cells transfected with the
indicatedconstructs.Westernblotswereperformed
using an anti-Flag antibody to detect EphA4, and
the resultant values were normalized to an actin
loading control. As previously reported, Cbl-B
promotes the degradation of EphA4 (Sharfe et al.,
2003). Cbl-B-mediated degradation of EphA4 is
not inhibited by Ube3A C833A, even though
Ube3A and Cbl-B can employ the same E2 con-
jugating enzyme when ubiquitinating substrates.
(D) Quantification of surface AMPAR expression
for E18 + 17 DIV hippocampal neurons trans-
fected with GFP and vector control, Ube3A, or
Ube3A C833A plasmids. At least 30 neurons
were imaged for each condition, and data are pre-
sented as mean ± SEM from three independent
experiments. * indicates statistical significance
p < 0.05, ANOVA, with Bonferroni correction for
multiple comparison.
(E) Quantification of surface AMPA receptor
expression on E18 + 14 DIV hippocampal neurons
transfected at 10 DIV with vector control, Arc,
Ube3A + Arc, ArcDUBD, or ArcDUBD + Ube3A.
Data are presented as mean ± SEM from three
independent experiments. * denotes statistical
significance p < 0.05, ANOVA, with Bonferroni
correction for multiple comparison.
(F) Quantification of surface AMPAR expression on
hippocampal neurons transfected with vector
control, Ube3A RNAi, Ube3A scrambled RNAi,
Arc RNAi, Arc scrambled RNAi, Ube3A RNAi and
scrambled control Arc RNAi, or Ube3A RNAi and
Arc RNAi. Data are presented as mean ± SEM
from three independent experiments. * denotes
statistical significance p < 0.05, ANOVA, with Bon-
ferroni correction for multiple comparison.
See also Figures S4 and S5.transfected neurons with wild-type Ube3A or Ube3A C833A.
Overexpression of Ube3A C833A but not wild-type Ube3A
causes a significant reduction in the number of AMPARs present
on the cell surface, suggesting that Ube3A ubiquitin ligase activity
is critical to the ability of Ube3A to promote expression of
AMPARs at synapses (Figure 5D and Figure S4A).
We asked whether the overexpression of Arc phenocopies
the loss of Ube3A and reduces AMPAR expression. As previ-
ously reported, the overexpression of Arc results in a decrease
in the plasma membrane expression of GluR1 (Chowdhury
et al., 2006; Rial Verde et al., 2006; Shepherd et al., 2006)
(Figure 5E). Coexpression of Ube3A with wild-type Arc attenu-
ates the ability of Arc to promote the endocytosis of GluR1.When a version of Arc lacking the UBD (ArcDUBD) was overex-
pressed in neurons, this form of Arc still promoted the endocy-
tosis of GluR1 but the co-expression of Ube3A did not reverse
this effect (Figure 5E). This suggests that Ube3A’s ability to
reduce the endocytosis of AMPARs is due to Ube3A-mediated
degradation of Arc.
To further investigate whether the ability of Ube3A to pro-
mote the expression of AMPARs at synapses is due to Ube3A-
dependent Arc ubiquitination and degradation, neurons were
transfected with shRNAs targeting Ube3A to reduce Ube3A
expression and/or shRNA directed against Arc to decrease Arc
expression and the effect on AMPAR cell surface expression
assessed. As described above, the expression of shRNAsCell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc. 711
targeting Ube3A in neurons led to a reduction in the number of
AMPARs at the neuronal cell surface (Figure 5F). Introduction
of shRNAs directed against Arc, but not control shRNAs, signif-
icantly reduced Arc expression in HEK293T cells (Figure S4B)
and when transfected into neurons caused a small but statisti-
cally insignificant increase in surface AMPAR expression
(Figure 5F). The failure of Arc shRNAs when transfected
alone to affect AMPAR surface expression likely reflects the
fact that given the low level of neuronal activity in these cultures
Arc levels are also quite low and only minimally affect AMPAR
surface expression. Consistent with this possibility, in older
cultures the expression of Arc shRNAs results in an increase in
AMPAR plasma membrane expression (Figure S4C). The lack
of significant Arc expression in younger neuronal cultures may
also explain why we find that overexpression of Ube3A does
not significantly affect the plasma membrane expression of
AMPARs in younger neuronal cultures. Expression of shRNAs
against Ube3A together with an shRNA directed against Arc
blocked the ability of Ube3A shRNA to suppress AMPAR expres-
sion at synapses (Figure 5F and Figure S5). These findings
suggest that Ube3A promotes the expression of AMPARs at
the plasma membrane of synapses by ubiquitinating and degrad-
ing Arc and that in the absence of Ube3A there is an excess of Arc
protein, resulting in increased endocytosis of AMPARs.
Analysis of AMPAR Function in Ube3A Knockout Mice
These findings suggest that in AS, the absence of Ube3A activity
may lead to an increase in Arc expression, thereby resulting in
a reduction in the expression of AMPARs at synapses. To inves-
tigate this, we examined AMPAR expression and function at the
synapses of Ube3A knockout mice that display features of AS
(Jiang et al., 1998). We cultured neurons from Ube3A knockout
or wild-type mice and assessed the expression of AMPARs.
Ube3A knockout neurons had reduced GluR1 expression at
the plasma membrane of synapses when compared to wild-
type neurons (Figure 6A). This effect appears to be specific to
AMPARs as we observe no change in the surface expression
of NMDARs (Figure 6B). Expression of shRNAs targeting Arc in
Ube3A knockout neurons restores the expression of GluR1
surface expression in Ube3A knockout neurons (Figure 6C).
These experiments suggest that the excessive internalization
of AMPARs in Ube3A knockout neurons is likely a result of
a failure to ubiquitinate and degrade Arc.
To determine whether GluR1 expression at synapses is dysre-
gulated in Ube3A knockout neurons in the context of an intact
neuronal circuit, we employed array tomography, a technique
in which ultra-thin sections of brain tissue are stained, imaged,
and synapses visualized as a 3D reconstruction (Micheva and
Smith, 2007). We performed array tomography using anti-
GluR1 antibodies to visualize AMPARs and anti-SV2 antibodies
to mark presynaptic sites. The density of GluR1 puncta closely
apposed to an SV2 puncta is decreased in Ube3A knockout
mice (Figure 6D and Figure S6). The density of SV2 puncta
remained constant between the two genotypes, suggesting
that the decrease in GluR1 synaptic localization in Ube3A
knockout sections is not a result of fewer available presynaptic
sites and instead reflects a decrease in GluR1 expression at
synapses. In contrast, we found that the number of NR1 puncta712 Cell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc.associated with SV2 puncta was similar at the synapses in the
hippocampi of wild-type and Ube3A knockout mice, suggesting
that the expression of AMPARs is selectively decreased in the
brains of Ube3A knockout mice (Figures 6E and 6F and
Figure S6). This reduction in AMPAR expression at the synapses
of Ube3A knockout mice is not a result of decreased overall
expression of GluR1 as wild-type and Ube3A knockout mice
express similar levels of GluR1 and NR1 in their hippocampi
(Figure 6G).
To determine whether the decreased expression of AMPARs at
the synapses of Ube3A knockout mice results in a functional
decrease in synaptic transmission, whole-cell recordings were
made from CA1 hippocampal pyramidal neurons. We observe
a significant decrease in the ratio of AMPA to NMDA receptor-
mediated currents in Ube3A knockouts compared to wild-type
mice (Figures 7A and 7B). While this decrease in AMPA/NMDA
current receptor ratio could reflect either a decrease in AMPAR
or an increase in NMDAR currents, our findings that in Ube3A
knockout mice there is a decrease in AMPAR expression at
synapses but no change in NMDAR expression suggests that
the decrease in AMPA/NMDA current ratio is most likely due to a
decrease in AMPAR-mediated currents in Ube3A knockout mice.
As an independent means of assessing the effect of disrupting
Ube3A on AMPAR function, we recorded mEPSCs from wild-
type and Ube3A knockout hippocampal pyramidal neurons
in acute slice preparations. We observe a reduction in the
frequency of mEPSCs with no corresponding change in mIPSC
frequency or amplitude in Ube3A knockout neurons compared
to wild-type neurons (Figures 7C–7E and Figure S7). This
observation supports the conclusion that AMPAR expression
and function at synapses are significantly decreased in Ube3A
knockout neurons.
DISCUSSION
Although it has been appreciated for more than a decade that
mutation of Ube3A results in AS, remarkably little is understood
about the role of Ube3A in nervous system development and
function or why mutation of Ube3A results in the cognitive
impairment underlying AS. This lack of insight has hampered
the development of therapeutic strategies for treating AS, and
as a result there are currently no effective treatments for this
disorder. In this study, we demonstrate that in the absence
of synaptic activation, Ube3A and Arc are expressed at low
levels. However, in response to glutamate release at excitatory
synapses, Arc is induced with relatively rapid kinetics (Flavell
et al., 2006) and endocytoses AMPAR from the plasma
membrane. This induction of Arc is likely important for limiting
the level of neuronal excitation since Arc-mediated endocytosis
of AMPARs dampens neuronal excitability. However, the level of
Arc expression must be effectively regulated for synapses to
function appropriately. We find that Ube3A transcription is
induced postsynaptically upon glutamate release at synapses
with delayed kinetics relative to Arc and that Ube3A then
functions to control the level of Arc protein expression by
ubiquitinating and degrading Arc. In this way, Ube3A tempers
the Arc-mediated internalization of AMPARs. The absence of
Ube3A activity in Ube3A knockout mice results in increased
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Figure 6. Ube3A Knockout Mice Have
Fewer Synaptically Expressed AMPARs
(A) Quantification of plasma membrane expression
of AMPARs on P2 + 12 DIV hippocampal neurons
isolated from wild-type (WT) and Ube3A knockout
(KO) animals transfected at 8 DIV with GFP. At
least 40 neurons were imaged for each condition,
and data are normalized to wild-type and pre-
sented as mean ± SEM from three independent
experiments. * indicates statistical significance
p < 0.01, t test.
(B) Quantification of plasma membrane expres-
sion of NMDA receptors on P2 + 12 DIV hippo-
campal neurons isolated from wild-type (WT) and
Ube3A knockout (KO) animals transfected at
8 DIV with GFP. At least 24 neurons were imaged
for each condition, and data are normalized to
wild-type and presented as mean ± SEM from
three independent experiments.
(C) Quantification of plasma membrane expres-
sion of AMPA receptors on P2 + 12 DIV hippo-
campal neurons isolated from wild-type (WT)
and Ube3A knockout (KO) animals transfected
at 8 DIV with GFP and either vector control,
scrambled control shRNAs, or shRNAs targeting
Arc. At least 28 neurons were imaged for each
condition, and data are normalized to wild-
type transfected with control and presented as
mean ± SEM from three independent experi-
ments. * indicates statistical significance p < 0.01,
ANOVA, with Bonferroni correction for multiple
comparisons.
(D) Quantification of the number of colocalized
GluR1 and SV2 puncta in wild-type and Ube3A
knockout hippocampi. Data are presented as
mean ± SEM from three independent animals for
each genotype. * indicates statistical significance
p < 0.01, t test.
(E) Quantification of the number of colocalized
NR1 and SV2 puncta in wild-type and Ube3A
knockout hippocampi. Data are presented as mean ± SEM from three independent animals for each genotype. p > 0.05, t test.
(F) Analysis of the ratio of the density of GluR1 puncta that colocalize with SV2 to the density of NR1 puncta that colocalize with SV2 obtained from (D) and (E).
* indicates statistical significance p < 0.01, t test.
(G) Quantitative western blot analysis of protein lysates prepared from the hippocampi of P21 wild-type and Ube3A knockout mice using anti-NR1 (left) and anti-
GluR1 (right) antibodies. Band intensity was normalized to the intensity of actin to control for differences in protein concentration. Data are presented as mean ±
SEM from three independent experiments.
See also Figure S6.levels of Arc, and excessive internalization of AMPARs, leading
to fewer synapses that express AMPARs at the plasma mem-
brane and to defects in synaptic transmission.
Consistent with these observations, a recent study has
demonstrated that Ube3A plays a role in experience-dependent
synaptic plasticity (Yashiro et al., 2009). Although Ube3A is not
required for the initial sensory-independent stages of synapse
development, Ube3A is necessary for sensory experience-
driven maturation of excitatory circuits, as Ube3A knockout
mice have deficits in LTP, LTD, and decreased mEPSCs in visual
cortex. The observation that Ube3A plays a role in experience-
driven synaptic plasticity may be explained by our finding that
both Arc and Ube3A transcription are induced by sensory expe-
rience and that in response to neuronal activity in the absence of
Ube3A, there is excessive accumulation of Arc and increased
internalization of AMPARs. As AMPARs play a central role inneurotransmission and information processing, this defect in
AMPAR expression and function in the absence of Ube3A is
likely to explain, at least in part, the deficits in synaptic plasticity
observed in the absence of Ube3A.
Our findings suggest that AS may be caused by the disruption
of a crucial step in experience-dependent synaptic development
and provide evidence that the neuronal activity-regulated gene
program plays a key role in human cognitive development.
Further support for this hypothesis comes from the observation
that mutation of another activity-regulated MEF2 target gene,
Slc9A6, results in phenotypes that mimic AS (Gilfillan et al.,
2008). Recent studies have shown that additional components
of the activity-regulated gene program including L-VSCC,
RSK2, MeCP2, CBP, PDCH10, and DIA1 are mutated in human
disorders, particularly epilepsy and ASDs (reviewed in Greer
and Greenberg, 2008). These findings suggest that furtherCell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc. 713
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Figure 7. Analysis of Synaptic Function in
the Hippocampi of Ube3A Knockout Mice
(A) Representative traces of currents evoked while
holding the neuron at 70 or +40 mV to measure
AMPAR- or NMDAR-mediated currents, respec-
tively. Examples are shown from a control (left)
and Ube3A knockout (right) neuron. Currents are
scaled by the current amplitude measured
between 50 and 70 ms after the peak of the evoked
current at +40 mV to highlight the relative changes
in AMPAR-mediated current.
(B) A summary histogram of AMPA/NMDA
receptor-mediated current ratios presented as
the geometric mean ± SEM. At least 15 cells
were analyzed per condition. * p < 0.05 by students
t test of the geometric means for each neuron.
(C) Representative mEPSC traces of hippocampal
neurons from wild-type (top) and Ube3A knockout
(bottom) slices.
(D) Quantification of mEPSC frequency from wild-
type (black line) and Ube3A knockout (red line)
mice. Data are presented as cumulative probability
plots of interevent intervals and represent recordings from at least 14 neurons from at least three independent animals of each genotype. A significant difference
was observed between wild-type and Ube3A knockout mice, p < 0.01 by Kolmogorov-Smirnov (KS) test.
(E) Quantification of mEPSC amplitude from wild-type (black line) and Ube3A knockout (red line) mice. Data are presented as cumulative probability plots and
represent recordings from at least 14 neurons from at least three independent animals of each genotype. No statistically significant difference was observed
between wild-type and Ube3A knockout mice by KS test.
See also Figure S7.investigation into the regulation and function of Ube3A, and the
activity-dependent gene program in general, will provide new
insight into the mechanisms controlling human cognitive devel-
opment, and how mutations that disrupt this process lead to
developmental disabilities, including ASDs.
The finding that disruption of Ube3A activity leads to
a decrease in AMPAR expression at synapses suggests that
drugs that promote AMPAR expression at synapses might
reverse symptoms associated with AS. Studies of another
human disorder, fragile X syndrome (FXS), where a decrease in
AMPAR expression at synapses has been observed suggest
that this type of therapeutic strategy has potential. In FXS, the
decrease in AMPAR expression at synapses is due to excessive
mGluR5 signaling, resulting in increased Arc translation and
excessive AMPAR internalization (Do¨len and Bear, 2008; Park
et al, 2008). In a mouse model of FXS, injection of the mGluR5
antagonist MPEP restored surface expression of AMPARs and
prevented the symptoms associated with FXS (Do¨len et al.,
2007; Nakamoto et al., 2007; Yan et al., 2005). These results
have led to the development of more specific mGluR5 antago-
nists that are now entering clinical trials for the treatment of
FXS. It is possible that similar approaches will also be effective
for treating AS.
A recent study demonstrated that the mutation of an inhibitory
phosphorylation site of aCaMKII rescues many behavioral defi-
cits exhibited by Ube3A-deficient mice, suggesting that subtle
genetic manipulations can reverse Ube3A loss-of-function
phenotypes (van Woerden et al., 2007). An intriguing aspect of
this finding is that increasing CamKII activity results in increased
AMPAR expression at synapses (Rose et al., 2009) and this may
explain why increased CaMKII activity rescues phenotypes
associated with the loss of Ube3A.714 Cell 140, 704–716, March 5, 2010 ª2010 Elsevier Inc.Although our results provide hope that it will be possible to
develop therapies for treating individuals with AS, it is also likely
that the defect in AMPAR expression at synapses is not the only
thing that has gone awry in AS. For example, it is not obvious
how impaired AMPAR receptor function results in an increased
susceptibility to seizures and thus it is likely that Ube3A sub-
strates in addition to Arc play roles in nervous system develop-
ment. In addition, individuals with AS have sleep disturbances,
hyperactivity, inappropriate laughter, and movement disorders.
Given the broad phenotypic consequences of AS, it is likely
that the disruption of the degradation of a number of Ube3A
substrates contributes to AS. In the present study, we have
defined a Ube3A binding domain that has aided in the identifica-
tion of new Ube3A substrates. One of these substrates is the
RhoGEF ephexin5, which plays an important role in restricting
the number of synapses formed by a neuron (S.S. Margolis
and M.E.G., unpublished data). We have also identified Sacsin
as a Ube3A substrate that is mutated in Charlevoix-Saguenay
spastic ataxia, and it is intriguing to speculate that in AS the
absence of Ube3A-mediated ubiquitination of Sacsin may
contribute to the movement disorders associated with AS. In
addition to ephexin5 and Sacsin, we have identified a number
of other proteins that contain the UBD. It will be important in
the future to determine how these substrates work together
with Ube3A to fine tune synapse development.
EXPERIMENTAL PROCEDURES
Cell Cultures, Transfections, and Infections
HEK293T cells and hippocampal neurons were cultured, transfected, and
infected as previously described (Flavell et al., 2006). Organotypic slice
cultures were prepared from P3-6 rat or mouse brains, and 350 mm slices of
hippocampus were prepared and transfected as described previously (Zhou
et al., 2006). Acute slices were prepared from P15–18 mice as described previ-
ously (Lin et al., 2008).
Mice
Ube3A knockout mice were obtained from The Jackson Laboratory, strain
129-Ube3atm1Alb/J, from stock number 004477. HA-ubiquitin mice were previ-
ously described (Ryu et al., 2007). Seizure and enriched environment experi-
ments were carried as described in the Extended Experimental Procedures.
Quantitative Real-Time PCR
PCR was carried out according to standard procedures. Specific primers are
listed in the Extended Experimental Procedures.
Chromatin Immunoprecipitation
Details of the chromatin immunoprecipitation and the primers used are
described in the Extended Experimental Procedures.
Image Analysis
Images were acquired on a Zeiss LSM5 Pascal confocal microscope and spine
and synapse analysis was performed as previously described (see the
Extended Experimental Procedures).
Plasmids
Details of plasmid preparation are available in the Extended Experimental
Procedures.
Ubiquitination Assay and In Vitro Binding
Two micrograms of Arc C-terminal protein (132–396 aa) was incubated with
2 mg of GST-WT or mutant Ube3A (C833A) in binding buffer (20 mM Tris-
HCL [pH 7.4], 50 mM NaCl, 4 mM ATP, 10 mM MgCl2, 0.2 mM dithiothreitol,
and 1% Triton X-100). After 2 hr of mixing at 4C, glutathione-Sepharose
beads (GE Healthcare) were added and incubated for another 2 hr. The beads
were washed twice with PBS + 1% Triton X-100 and twice with PBS. Proteins
were eluted with SDS sample buffer and analyzed by western blotting. For
in vitro ubiquitination assays, 1 mg Arc C-terminal protein was incubated
with 50 ng E1, 100 ng UbcH7, 200 ng each of WT or mutant (C833A) Ube3A,
and 4 mg ubiquitin (BostonBiochem) in 20 mM Tris-HCL (pH 7.4), 50 mM
NaCl, 4 mM ATP, 10 mM MgCl2, and 0.2 mM dithiothreitol. Reactions were
terminated after 2 hr at 30C by the addition of SDS sample buffer and were
analyzed by western blotting.
Surface GluR1 Staining
Immunostaining of surface GluR1 receptors was performed as previously
described (Chowdhury et al., 2006).
Electrophysiology
Electrophysiology was performed using standard methods (see the Extended
Experimental Procedures for more detail).
Ube3A Knockout Cultures
Hippocampal cultures were prepared from Ube3A knockout and wild-type
littermate mice at P2 using a protocol adopted from K. Condon and M. Ehlers.
In brief, hippocampi were dissected in Dissociation Media (DM) (0.3% BSA,
12 mM MgSO4, 10 mM HEPES, 0.6% glucose in Hank’s Balanced Salt Solu-
tion). Hippocampi were then placed in a papain solution 30 Units/mL in DM
for 15 min before resuspension in Neurobasal Medium. The cells were then
plated on glass coverslips that had been coated overnight with PDL.
Array Tomography
Array tomography was performed as described (Micheva and Smith, 2007)
with modifications as described in the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at doi:10.1016/j.cell.
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